The changes in cardiovascular prevention practice between 1995–2017 in the Czech Republic: a comparison of EUROASPIRE I, II, III, IV and V study

Czech version

Authors: Otto Mayer Jr ^1,2; Jan Bruthans ^1,3; Martina Rychecká Za Investigátory Studií Euroaspire I V V České Republice ¹
Authors‘ workplace: II. interní klinika LF UK a FN Plzeň ¹; Biomedicínské centrum LF UK v Plzni ²; Centrum kardiovaskulární prevence 1. LF UK a Thomayerovy nemocnice, Praha ³
Published in: Vnitř Lék 2018; 64(12): 1190-1199
Category: Original Contributions

Overview

Background:

Appropriate secondary prevention after myocardial infarction is at least similarly important than the management of acute phase. A serie of EUROASPIRE surveys evaluated the real implementation of secondary prevention principles (as defined by current “Guidelines”) into clinical practice in stable coronary heart disease (CHD) patients. This analysis presented changes in adherence to recommended principles overtime, between 1995 and 2017 in Czech cohorts of EUROASPIRE project.

Methods:

Five independent descriptive surveys were undertaken in 1995/1996, 1999/2000, 2006/2007, 2012/2013 and 2016/2017. Consecutive patients suffering for acute coronary event and/or revascularization procedure were identified and examined at least 6 months afterwards.

Results:

The study population included 5 cohorts of 331, 410, 489, 493 and 406 patients. The prescription of basic pharmacotherapy markedly improved, namely use of statins increased more than 12 times (from 7 to 92 %). Proportion of patients who underwent revascularization increased from 49 % to 94 %. Prevalence of hypercholesterolemia and raised blood pressure significantly decreased from 98 % to 52 %, and from 64 % to 49 %, respectively. Proportion of active smokers did not change significantly. Prevalence of overt diabetes increased more than twice between 1995 and 2006, while decreased again afterwards (but still remained higher than baseline prevalence).

Conclusion:

Despite that the adherence to recommendations for secondary prevention markedly improved in single factors, global achievement of desired target remained far from being optimal.

Key words:

coronary heart disease – EUROASPIRE – guidelines – mortality – secondary prevention

Sources

Pyorala K, De Backer G, Graham I et al. Prevention of coronary heart di1. Pyorala K, De Backer G, Graham I et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15(10): 1300–1331.
Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19(10): 1434–1503.
De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17): 1601–1610.
Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1-S113. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjr.0000277983.23934.c9>.
Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635–1701. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs092>.Erratum in Eur Heart J 2012; 33(17): 2126.
EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18(10): 1569–1582. Erratum in Eur Heart J 1998; 19(2): 356–357.
Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22(7): 554–572. Dostupné z DOI: <http://dx.doi.org/10.1053/euhj.2001.2610>.
Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 121–137. Dostupné z DOI: <http://dx.doi.org/10.1097/HJR.0b013e3283294b1d>.
Kotseva K, Wood D, De Bacquer D et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016; 23(6): 636–648. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487315569401>.
Bruthans J, Cifkova R, Lanska V et al. Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. Eur J Prev Cardiol 2014; 21(7): 829–839. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487312469476>.
Norgaard ML, Andersen SS, Schramm TK et al. Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction – a nationwide study. Diabetologia 2010; 53(8): 1612–1619. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–010–1783-z>.
Movsisyan NK, Sochor O, Kralikova E et al. Current and past smoking patterns in a Central European urban population: a cross-sectional study in a high-burden country. BMC Public Health 2016; 16: 571. Dostupné z DOI: <http://dx.doi.org/10.1186/s12889–016–3216–5>.
Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23(11): np1-np96. Dostupné z DOI: <http://dx.doi.org/10.1177/2047487316653709>.
James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363(10): 905–917. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1003114>.
Turnbull F, Neal B, Ninomiya T et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336(7653): 1121–1123. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.39548.738368.BE>.
Wright jr. JT, Williamson JD, Whelton PK et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103–2116. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1511939>.
Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267–1278. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67394–1>. Erratum in Lancet 2005; 366(9494):1358.Lancet 2008; 371(9630): 2084.
Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110(2): 227–239. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000133317.49796.0E>.
Vorlíčková P, Mayer O, Bruthans J et al. The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Vasa 2018; June 6. Dostupné z DOI: <http://dxdoi.org/10.1016/j.crvasa.2018.05.002>.
Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18) :1713–1722. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1615664>.
Slezak D, Mayer O, Bruthans J et al. The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients. Exp Clin Endocrinol Diabetes 2018; Aug 29. Dostupné z DOI: <http://dx.doi.org/10.1055/a-0684–9601>.
De Bacquer D, Dallongeville J, Kotseva K et al. Residual risk of cardiovascular mortality in patients with coronary heart disease: the EUROASPIRE risk categories. Int J Cardiol 2013; 168(2): 910–914. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ijcard.2012.10.051>.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.